局限性前列腺癌中UGT2B17胞质表达的预后意义:来自加拿大前列腺癌生物标志物网络和PROCURE多机构队列的见解
研究基于加拿大前列腺癌生物标志物网络(n=1454)和PROCURE(n=1562)两个组织芯片队列,评估前列腺切除标本中UGT2B17表达(>25%)与致死性前列腺癌的关联。结果显示,肿瘤UGT2B17高表达与雄甾酮葡萄糖苷酸水平升高60%相关,并与转移/去势抵抗进展风险及前列腺癌特异性死亡风险增加相关。
要点
- 肿瘤UGT2B17表达>25%与局限性前列腺癌进展至转移/CRPC及前列腺癌特异性死亡风险增加相关。
- UGT2B17高表达与雄甾酮葡萄糖苷酸(主要循环无活性雄激素代谢物)水平升高60%相关。
- UGT2B17可能通过增加雄激素灭活创造低雄激素肿瘤环境,驱动侵袭性表型。
核心结论
- 肿瘤UGT2B17高表达与局限性前列腺癌进展至转移/CRPC及前列腺癌特异性死亡风险增加相关。
- UGT2B17通过增加雄激素灭活影响激素水平,可能创造低雄激素肿瘤环境驱动侵袭性表型。
研究设计与样本
- 预设假设:原发肿瘤UGT2B17表达>25%与侵袭性疾病表型相关。
- 分析两个高密度前列腺肿瘤组织芯片数据集:加拿大前列腺癌生物标志物网络生物库(n=1454)和PROCURE队列(n=1562)。
- 采用Kaplan-Meier和Cox比例风险比分析评估无转移生存、CRPC和前列腺癌特异性死亡。
- 通过质谱法测量血浆样本中的类固醇水平,并使用线性回归模型评估基于肿瘤UGT2B17表达的激素水平变化。
主要发现
- UGT2B17与预后因素相关,并与雄甾酮葡萄糖苷酸水平升高60%相关。
- Kaplan-Meier和多变量Cox分析显示,肿瘤UGT2B17较高与进展至转移/CRPC阶段风险增加及前列腺癌特异性死亡相关。
临床怎么用
- UGT2B17表达可能作为局限性前列腺癌的预后标志物,识别进展至不可治愈阶段风险增加的患者亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Prostate cancer (PCa) is hormone dependent, with UDP-glucuronosyltransferase 2B17 (UGT2B17) playing a central role in androgen inactivation. This study aimed to evaluate whether UGT2B17 expression in prostatectomy specimens can serve as a prognostic marker for lethal PCa. METHODS: A prespecified hypothesis posited that UGT2B17 expression (>25%) in primary tumors is associated with an aggressive disease phenotype, leading to metastasis, castration resistance (castration-resistant PCa [CRPC]), and mortality in men initially diagnosed with localized disease. Two high-density prostate tumor tissue microarray datasets were analyzed: the first from the Canadian Prostate Cancer Biomarker Network biobank (n = 1454) and the second from the PROCURE cohort (n = 1562). Kaplan-Meier and Cox proportional hazard ratio analyses were used to evaluate metastasis-free survival, CRPC, and PCa-specific mortality. Steroid levels were measured in plasma samples by mass spectrometry, and a linear regression model was used to evaluate variations in hormone levels based on tumoral UGT2B17 expression. KEY FINDINGS AND LIMITATIONS: UGT2B17 was associated with prognostic factors and linked to elevated levels of androsterone glucuronide (60%), the major circulating androgen-inactive metabolite, which is inactivated by UGT2B17. Kaplan-Meier and multivariable Cox analyses revealed that higher tumoral UGT2B17 is associated with an increased risk of progression to metastatic/CRPC stages and with PCa-specific mortality. CONCLUSIONS AND CLINICAL IMPLICATIONS: UGT2B17 expression influences hormone levels and identifies a subset of patients at an increased risk of progression to an incurable disease stage. Findings support the notion that enhanced UGT2B17, through increased androgen inactivation, creates a low-androgen tumor environment that drives tumor progression to a more aggressive phenotype.
引用
- Uchil A, Lacombe L, Hovington H, et al. Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts. Eur Urol Oncol. 2025. PMID: 40998686. doi:10.1016/j.euo.2025.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。